Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Voting Common Stock^F1,F5,F6	Jun 11, 2026	C	122,990	—	A	122,990	I	Through Deerfield Private Design Fund III, L.P.
Voting Common Stock^F1,F5,F6	Jun 11, 2026	C	122,990	—	A	122,990	I	Through Deerfield Healthcare Innovations Fund, L.P.
Voting Common Stock^F2,F5,F6	Jun 11, 2026	C	149,238	—	A	272,228	I	Through Deerfield Private Design Fund III, L.P.
Voting Common Stock^F2,F5,F6	Jun 11, 2026	C	149,238	—	A	272,228	I	Through Deerfield Healthcare Innovations Fund, L.P.
Voting Common Stock^F3,F5,F6	Jun 11, 2026	C	260,992	—	A	533,220	I	Through Deerfield Private Design Fund III, L.P.
Voting Common Stock^F3,F5,F6	Jun 11, 2026	C	260,992	—	A	533,220	I	Through Deerfield Healthcare Innovations Fund, L.P.
Voting Common Stock^F4,F5,F6	Jun 11, 2026	C	407,132	—	A	940,352	I	Through Deerfield Private Design Fund III, L.P.
Voting Common Stock^F4,F5,F6	Jun 11, 2026	C	407,132	—	A	940,352	I	Through Deerfield Healthcare Innovations Fund, L.P.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F1,F5,F6	—	Jun 11, 2026	C	166,070	D	—	—	Voting Common Stock	122,990	I
Series A Preferred Stock^F1,F5,F6	—	Jun 11, 2026	C	166,070	D	—	—	Voting Common Stock	122,990	I
Series B Preferred Stock^F2,F5,F6	—	Jun 11, 2026	C	143,650	D	—	—	Voting Common Stock	149,238	I
Series B Preferred Stock^F2,F5,F6	—	Jun 11, 2026	C	143,650	D	—	—	Voting Common Stock	149,238	I
Series C Preferred Stock^F3,F5,F6	—	Jun 11, 2026	C	246,732	D	—	—	Voting Common Stock	260,992	I
Series C Preferred Stock^F3,F5,F6	—	Jun 11, 2026	C	246,732	D	—	—	Voting Common Stock	260,992	I
Series D Preferred Stock^F4,F5,F6	—	Jun 11, 2026	C	464,550	D	—	—	Voting Common Stock	407,132	I
Series D Preferred Stock^F4,F5,F6	—	Jun 11, 2026	C	464,550	D	—	—	Voting Common Stock	407,132	I

Explanation of responses

F1Each share of Series A Preferred Stock automatically converted into approximately 0.7406 shares of the Issuer's voting common stock upon the closing of the Issuer's initial public offering (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026).
F2Each share of Series B Preferred Stock automatically converted into approximately 1.0389 shares of the Issuer's voting common stock upon the closing of the Issuer's initial public offering (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026).
F3Each share of Series C Preferred Stock automatically converted into approximately 1.0578 shares of the Issuer's voting common stock upon the closing of the Issuer's initial public offering (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026).
F4Each share of Series D Preferred Stock automatically converted into approximately 0.8764 shares of the Issuer's voting common stock upon the closing of the Issuer's initial public offering (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026).
F5This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield Innovations" and together with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds.
F6In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by each Fund is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.